title: Human complement component C1q inhibits the infectivity of cell-free HTLV-I.
abstract: Human T cell leukemia virus type I (HTLV-I) is a retrovirus that is not lysed by human serum or complement. It has not been determined, however, whether HTLV-I directly binds to complement components or whether it retains infectivity after incubation with human serum. We investigated the effects of human serum on the infectivity of cell-free HTLV-I produced by human and animal cells. Plating of vesicular stomatitis virus (HTLV-I) pseudotypes prepared in cat or human cells and formation of HTLV-I DNA after infection of cell-free HTLV-I produced by cat or human cells were markedly inhibited by treatment with fresh human serum, but not by heat-inactivated serum. HTLV-I infection was also inhibited by treatment with C2-, C3-, C6-, or C9-deficient serum, but not by C1q-deficient serum. Inhibitory activities of normal human serum against HTLV-I were neutralized by anti-C1q serum. Furthermore, purified C1q inhibited HTLV-I infection. The direct binding of C1q to HTLV-I was confirmed by comigration of C1q with HTLV-I virion upon sucrose density gradient ultracentrifugation of HTLV-I virion treated with C1q. Binding assay using synthetic envelope peptides indicated that C1q bound to an extramembrane region of the gp21 transmembrane protein. These findings indicate that the human complement component C1q inactivates HTLV-I infectivity.
authors.affiliation: Second Department of Surgery, Gunma University School of Medicine, Maebashi, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Ikeda
authors.forename: Y
authors.initials: Y
authors.lastname: Haraguchi
authors.forename: A
authors.initials: A
authors.lastname: Jinno
authors.forename: Y
authors.initials: Y
authors.lastname: Iino
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
authors.forename: H
authors.initials: H
authors.lastname: Shiraki
authors.forename: H
authors.initials: H
authors.lastname: Hoshino
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000276:immunology*; D002415:Cats; D002474:Cell-Free System / Q000276:immunology; D015922:Complement C1q / Q000378:metabolism / Q000502:physiology*; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000172:deficiency; D003602:Cytotoxicity, Immunologic; D015686:Gene Products, env / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism; D015490:HTLV-I Infections / Q000097:blood / Q000276:immunology* / Q000821:virology; D015368:Human T-lymphotropic virus 1 / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology*; D009500:Neutralization Tests; D011485:Protein Binding / Q000276:immunology; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology; D014771:Virion / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D015686:Gene Products, env; D006023:Glycoproteins; D007166:Immunosuppressive Agents; D015922:Complement C1q; D003165:Complement System Proteins